Rimegepant effective for migraine prevention: Lancet
USA: Rimegepant, when taken every other day, can help in the prevention of migraine, shows a recent phase 2/3 trial. The findings of the study, published in The Lancet, showed that the use of rimegepant had no unexpected or serious safety issues and its tolderability was same as that of placebo.
Rimegepant is an oral calcitonin gene-related peptide receptor (CGRP) antagonist that has shown safety and efficacy in the acute treatment of migraine. Robert Croop, Biohaven Pharmaceuticals, New Haven, USA, and colleagues aimed to compare the efficacy of rimegepant with placebo for preventive treatment of migraine.
For the purpose, the researchers performed a multicentre, phase 2/3, randomised, double-blind, placebo-controlled trial at 92 sites in the USA. It recruited 1591 participants with at least a 1-year history of migraine. After a 4-week observation period, 747 were randomized to receive either oral rimegepant 75 mg or matching placebo every other day for 12 weeks (double-blind treatment phase).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.